Loading
BIRC3 (Baculoviral IAP repeat-containing protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 4 more.
Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signalling and immunity, mitogenic kinase signalling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signalling and regulates both canonical and non-canonical NF-kappa-B signalling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signalling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.98, genetic association 0.00, somatic mutation 0.80, clinical 0.14). IntOGen calls it a driver in 2 cohorts (1 activating, 0 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Lung Squamous Cell Carcinoma.
In plain words · BIRC3 (Baculoviral IAP repeat-containing protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 4 more.
BIRC3 (Baculoviral IAP repeat-containing protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 4 more.
Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signalling and immunity, mitogenic kinase signalling and cell proliferation, as well as cell invasion and metastasis.
No product in this corpus aims at BIRC3 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a fusion partner (UniProt records a translocation); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA BIRC3: RNA tissue enhanced (intestine 84 nTPM, lymphoid tissue 132 nTPM); blood lineage group enriched (B-cells 210 nTPM, T-cells 84 nTPM); high antibody staining in 6 normal tissues; highest cancer staining melanoma (1 of 11 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Leukaemia, Skin cancer (all types), Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q13489; CIViC gene BIRC3; IntOGen BIRC3; Human Protein Atlas BIRC3 tissue; Open Targets ENSG00000023445 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Rothe et al, Cell, 1995, "The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins". Source.
Sources: HGNC HGNC:591 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q13489 (protein name, function text, keywords and locations (REST API)); CIViC gene BIRC3 (2 evidence items, 0 assertions, 2 variants; diseases: Mantle Cell Lymphoma, Chronic Lymphocytic Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000023445 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.56, non-Hodgkin lymphoma 0.62, skin cancer 0.55, leukaemia 0.59 (GraphQL API, CC0)); IntOGen BIRC3 (driver in 2 cohorts (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signalling and immunity, mitogenic kinase signalling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signalling and regulates both canonical and non-canonical NF-kappa-B signalling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signalling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signalling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Location: Cytoplasm; Nucleus (UniProt). Locus 11q22.2 (HGNC).
RNA: tissue enhanced (intestine 84 nTPM, lymphoid tissue 132 nTPM), detected in many normal tissues. Blood: group enriched (B-cells 210 nTPM, T-cells 84 nTPM).
Medium: Colon, Duodenum, Lymph node, Placenta, Rectum, Seminal vesicle, Skin, Urinary bladder.
Medium only: glioma, head and neck cancer, lymphoma, ovarian cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"BIRC3" OR ABSTRACT:"BIRC3" OR TITLE:"baculoviral IAP repeat containing 3" OR ABSTRACT:"baculoviral IAP repeat containing 3" OR TITLE:"Baculoviral IAP repeat-containing protein 3" OR ABSTRACT:"Baculoviral IAP repeat-containing protein 3" OR TITLE:"cIAP2" OR ABSTRACT:"cIAP2" OR TITLE:"hiap-1" OR ABSTRACT:"hiap-1" OR TITLE:"RNF49" OR ABSTRACT:"RNF49") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BIRC3, not a curated reading list.
Shares Microbiome-tumour interactions, Inflammation & NF-κB, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Microbiome-tumour interactions, Inflammation & NF-κB, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Microbiome-tumour interactions, Inflammation & NF-κB, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Leukaemia (all types), Mantle cell lymphoma, Chronic lymphocytic leukaemia, Skin cancer (all types).
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Skin cancer (all types), Acute lymphoblastic leukaemia.
Shares Marginal zone lymphoma, Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia.
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Skin cancer (all types), CIViC.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.